Abstract
Type 2 diabetes management can be improved by the use of second-generation basal insulin analogues as the first choice on commencement of insulin, in this instance focussing on insulin glargine 300 U/mL (Gla-300). The clinical application of the use of Gla-300 include advantages such as less intra- and interpatient variability in glucose control resulting in rather less hypoglycaemia, longer duration of action and greater flexibility in the timing of administration thus suiting a wide range of patient presentations. Funding: Sanofi Australia.
| Original language | English |
|---|---|
| Pages (from-to) | 1987-1994 |
| Number of pages | 8 |
| Journal | Diabetes Therapy |
| Volume | 10 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2019 |
Open Access - Access Right Statement
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.Keywords
- case studies
- non-insulin-dependent diabetes
- treatment
